Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines

244 611

Cited 0 times in

Cited 15 times in

Authors: Sollip Kim ; Yeo-Min Yun ; Hyo-Jin Chae ; Hyun-Jung Cho ; Misuk Ji ; In-Suk Kim ; Kyung-A Wee ; Woochang Lee ; Sang Hoon Song ; Hye In Woo ; Soo-Youn Lee ; Sail Chun

MeSH: Anticoagulants/therapeutic use ; Antidepressive Agents/therapeutic use ; Antimetabolites, Antineoplastic/therapeutic use ; Antitubercular Agents/therapeutic use ; Arylamine N-Acetyltransferase/genetics ; Coronary Artery Disease/drug therapy ; Coronary Artery Disease/genetics ; Cytochrome P-450 CYP2C19/genetics ; Cytochrome P-450 CYP2C9/genetics ; Cytochrome P-450 CYP2D6/genetics ; Depressive Disorder/drug therapy ; Depressive Disorder/genetics ; Genotype ; Isoniazid/therapeutic use ; Laboratories, Hospital/standards ; Methyltransferases/genetics ; Pharmacogenomic Testing/methods* ; Pharmacogenomic Testing/standards ; Platelet Aggregation Inhibitors/therapeutic use ; Pulmonary Embolism/drug therapy ; Pulmonary Embolism/genetics ; Ticlopidine/analogs & derivatives ; Ticlopidine/therapeutic use ; Tuberculosis/drug therapy ; Tuberculosis/genetics ; Vitamin K Epoxide Reductases/genetics ; Warfarin/therapeutic use

Keywords: Clinical laboratory ; Korea ; Pharmacogenetics ; Practice guideline ; Testing

Abstract: Pharmacogenetic testing for clinical applications is steadily increasing. Correct and adequate use of pharmacogenetic tests is important to reduce unnecessary medical costs and adverse patient outcomes. This document contains recommended pharmacogenetic testing guidelines for clinical application, interpretation, and result reporting through a literature review and evidence-based expert opinions for the clinical pharmacogenetic testing covered by public medical insurance in Korea. This document aims to improve the utility of pharmacogenetic testing in routine clinical settings.